...
首页> 外文期刊>Journal of Medicinal Chemistry >2-aminothienopyridazines as novel adenosine A(1) receptor allosteric modulators and antagonists
【24h】

2-aminothienopyridazines as novel adenosine A(1) receptor allosteric modulators and antagonists

机译:2-氨基噻吩并哒嗪作为新型腺苷A(1)受体变构调节剂和拮抗剂

获取原文
获取原文并翻译 | 示例

摘要

A pharmacophore-based screen identified 32 compounds including ethyl 5-amino-3-(4-tert-butylphenyl)-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine -1-carboxylate (8) as a new allosteric modulator of the adenosine A(1) receptor (A(1)AR). On the basis of this lead, various derivatives were prepared and evaluated for activity at the human A(1)AR. A number of the test compounds allosterically stabilized agonist-receptor-G protein ternary complexes in dissociation kinetic assays, but were found to be more potent as antagonists in subsequent functional assays of ERK1/2 phosphorylation. Additional experiments on the most potent antagonist, 13b, investigating A(1)AR-mediated [S-35]GTP gamma S binding and [H-3]CCPA equilibrium binding confirmed its antagonistic mode of action and also identified inverse agonism. This study has thus identified a new class of A(1)AR antagonists that can also recognize the receptor's allosteric site with lower potency.
机译:基于药效团的筛选方法确定了32种化合物,包括5-氨基-3-(4-叔丁基苯基)-4-氧代-3,4-二氢噻吩并[3,4-d]哒嗪-1-羧酸乙酯(8)腺苷A(1)受体(A(1)AR)的新的变构调节剂。在此基础上,制备了各种衍生物并评估了其对人A(1)AR的活性。在离解动力学测定中,许多受试化合物具有变构稳定的激动剂-受体-G蛋白三元复合物,但在随后的ERK1 / 2磷酸化功能测定中被发现更有效地作为拮抗剂。关于最有效的拮抗剂13b的其他实验,研究了A(1)AR介导的[S-35] GTPγS结合和[H-3] CCPA平衡结合,证实了其拮抗作用方式,并且还确定了反向激动作用。因此,这项研究确定了新型的A(1)AR拮抗剂,它们也可以以较低的效力识别受体的变构位点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号